Home・Stock List・Viking Therapeutics Inc

Viking Therapeutics Inc

Closed

SectorHealthcare

34.11 2.49

Buy Sell

Overview

Share price change

24h

Current

Min

33.78

Max

34.29

Key metrics
By Trading Economics
Income	30M -128M
EPS	-1.1
Employees	65
EBITDA	30M -128M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+168.77% upside

Dividends
By Acuity
Next Earnings	21 Oct 2026

Market Stats
By TradingEconomics
Market Cap	-245M 3.8B
Previous open	31.62
Previous close	34.11

News Sentiment

By Acuity

50%

116 / 340 Healthcare

Viking Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

7 Aug 2026, 19:36 UTC

Social Media

Viking Therapeutics is rising amid broader market gains and anticipation of VK2809 trial results, with analysts noting potential for improved market position.

6 Aug 2026, 23:16 UTC

Social Media

Viking Therapeutics Inc gains in after-market hours amid discussions on pharmacokinetic modeling and anticipated VKTX maintenance readout results.

5 Aug 2026, 22:51 UTC

Viking Therapeutics Inc. shares are lower in after-market hours, continuing a decline from Wednesday's close amid unusual volatility and trading below the 20-day moving average.

4 Aug 2026, 23:02 UTC

Social Media

Viking Therapeutics Inc shares are lower in after-market hours amid routine trading. The stock remains below its 20-day moving average.

3 Aug 2026, 23:06 UTC

Viking Therapeutics shares are higher in after-market trading, reflecting positive sentiment from stronger-than-expected manufacturing PMI data indicating sector growth.

31 Jul 2026, 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

30 Jul 2026, 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

29 Jul 2026, 23:21 UTC

Social Media

News

Viking Therapeutics reported a Q2 loss of $1.10 per share, better than expected. The company highlighted progress in its obesity treatment pipeline.

28 Jul 2026, 23:11 UTC

News

Viking Therapeutics shares are lower in after-market hours amid ongoing challenges and a significant decline over the past two years. Analysts maintain a bullish outlook.

27 Jul 2026, 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

25 Jul 2026, 00:01 UTC

Viking Therapeutics Inc shares are lower in after-market trading, continuing a trend of four consecutive sessions finishing down. No specific news was identified.

24 Jul 2026, 21:01 UTC

Viking Therapeutics Inc. is higher in after-market trading, reversing recent losses despite no specific news driving the price movement.

23 Jul 2026, 23:46 UTC

Event

Viking Therapeutics shares are higher in after-market trading ahead of Q2 earnings, with estimated EPS of -$1.21, up from -$0.58.

22 Jul 2026, 23:36 UTC

Viking Therapeutics Inc. shares showed little change during after-market hours, trading within a narrow range and settling near unchanged levels.

Peer Comparison

Price change

Viking Therapeutics Inc Forecast

Price Target

By TipRanks

168.77% upside

12 Months Forecast

Average 92.08 USD 168.77%

High 114 USD

Low 70 USD

Based on 14 Wall Street analysts offering 12 month price targets forViking Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to Viking Therapeutics Inc - Dist in the past 3 months.

Sentiment

By Acuity

116 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.